Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of sebetralstat (KVD900) for on-demand treatment of hereditary angioedema attacks
2021-001176-42Phase 3Active
- Sponsor
- KalVista Pharmaceuticals
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sebetralstat in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2), sponsored by KalVista Pharmaceuticals. Primary endpoint: Long-term safety (adverse events). Started Jul 2022; status: active.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on 2021-001176-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001176-42.